News
Patient recruitment completed in landmark Tourette syndrome study
2022-10-14 09:50
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought
2022-09-05 13:24
A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME CEO Peter Nordkild: “If full clinical development is successful, Sepranolone will be the...
Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen
2022-06-23 11:15
On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”)...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
2022-05-04 11:29
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2021...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)
2022-04-05 08:00
Asarina Pharma’s Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial...